---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-098335"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2026-08-18T20:06:04+00:00"
generated_at: "2026-08-18T20:07:08.649192+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance

## Summary
- Board approved 1-for-50 reverse stock split; effective at close of trading Aug 20, 2026; split-adjusted trading on Nasdaq Capital Market Aug 21, 2026 under LIMN.
- Outstanding shares would drop from 67,160,362 to ~1,343,208 (as of July 2, 2026); fractional shares rounded up; CUSIP changes to 53271X 207.
- Nasdaq Panel granted transfer to Capital Market effective Aug 4, 2026; must show $1.00 closing bid for 10 consecutive days by Sept 3, 2026 to regain compliance.
- Company had been non-compliant with MVLS, MVPHS, and bid price rules; regained compliance with stockholders' equity and MVPHS requirements.

## SEC filing metadata
- accession: 0001104659-26-098335
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2026-08-18T20:06:04+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465926098335/0001104659-26-098335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465926098335/tm2623497d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-098335
- JSON: https://secwatch.observer/filing/0001104659-26-098335.json
- Plain text: https://secwatch.observer/filing/0001104659-26-098335.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.